<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03860597</url>
  </required_header>
  <id_info>
    <org_study_id>R01MH094320</org_study_id>
    <nct_id>NCT03860597</nct_id>
  </id_info>
  <brief_title>Memantine Effects on Sensorimotor Gating and Neurocognition in Schizophrenia</brief_title>
  <official_title>Memantine Effects on Sensorimotor Gating and Neurocognition in Schizophrenia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of California, San Diego</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of California, San Diego</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This application seeks to determine if neurophysiological metrics of memantine (MEM)-enhanced
      early auditory information processing (EAIP) in schizophrenia (SZ) mediate gains in auditory
      processing fidelity (APF) and auditory learning.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">April 1, 2018</start_date>
  <completion_date type="Anticipated">March 2021</completion_date>
  <primary_completion_date type="Anticipated">March 2021</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Supportive Care</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>prepulse inhibition (PPI)</measure>
    <time_frame>7 and 14 days post baseline</time_frame>
    <description>Change from placebo measure in PPI</description>
  </primary_outcome>
  <primary_outcome>
    <measure>mismatch negativity (MMN)</measure>
    <time_frame>7 and 14 days post baseline</time_frame>
    <description>Change from placebo measure in MMN</description>
  </primary_outcome>
  <primary_outcome>
    <measure>gamma auditory steady-state response (ASSR)</measure>
    <time_frame>7 and 14 days post baseline</time_frame>
    <description>Change from placebo measure in ASSR</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">81</enrollment>
  <condition>Schizophrenia</condition>
  <condition>Schizo Affective Disorder</condition>
  <condition>Schizoaffective Disorder</condition>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>Memantine</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Memantine</intervention_name>
    <description>To assess the acute effects of MEM (0 vs. 20 mg) on measures of auditory processing fidelity, auditory learning and EAIP, in AP-medicated adult SZ patients and HS.</description>
    <arm_group_label>Memantine</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebos</intervention_name>
    <description>To assess the acute effects of MEM (0 vs. 20 mg) on measures of auditory processing fidelity, auditory learning and EAIP, in AP-medicated adult SZ patients and HS.</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  diagnosis of schizophrenia OR schizoaffective-depressed OR healthy subjects

          -  ages 18-50 for all subjects

          -  double barrier contraception for all subjects

          -  not pregnant for all subjects

        Exclusion Criteria:

          -  DSM-IV Axis I or II Diagnosis for for healthy subjects

          -  MEM or amantadine for patients

          -  current substance abuse for all subjects

          -  current recreational drug use for all subjects

          -  history of other significant medical illness (e.g. cancer, diabetes, heart disease,
             HIV, seizures) for all subjects

          -  open head injury or closed head injury with loss of consciousness &gt; 1 min for all
             subjects

          -  hearing or visual impairment for all subjects

          -  pregnancy for all subjects

          -  dementia for all subjects

          -  mental retardation for all subjects
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Jo Talledo Benrubi, B.A.</last_name>
    <phone>6195433093</phone>
    <email>atalledo@ucsd.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Neal Swerdlow, M.D., Ph.D.</last_name>
    <phone>6195436270</phone>
    <email>nswerdlow@ucsd.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Clinical Teaching Facility (CTF-B102) at UCSD Medical Center</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <zip>92103</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jo Talledo Benrubi, B.A.</last_name>
      <phone>619-543-3093</phone>
      <email>atalledo@ucsd.edu</email>
    </contact>
    <investigator>
      <last_name>Neal R. Swerdlow, M.D., Ph.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2020</verification_date>
  <study_first_submitted>February 28, 2019</study_first_submitted>
  <study_first_submitted_qc>February 28, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">March 4, 2019</study_first_posted>
  <last_update_submitted>January 7, 2020</last_update_submitted>
  <last_update_submitted_qc>January 7, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">January 9, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of California, San Diego</investigator_affiliation>
    <investigator_full_name>Neal R. Swerdlow, M.D., Ph.D.</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Disease</mesh_term>
    <mesh_term>Schizophrenia</mesh_term>
    <mesh_term>Psychotic Disorders</mesh_term>
    <mesh_term>Mood Disorders</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Memantine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

